FANG vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 14, 2026

FANG

57.6
AI Score
VS
FANG Wins

MRNA

39.1
AI Score

Investment Advisor Scores

FANG

58score
Recommendation
HOLD

MRNA

39score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric FANG MRNA Winner
Revenue 3.84B 534.00M FANG
Net Income 1.27B -2.13B FANG
Net Margin 33.0% -397.9% FANG
Operating Income 2.02B -2.20B FANG
ROE 8.2% -31.4% FANG
ROA 4.4% -19.4% FANG
Total Assets 29.00B 10.96B FANG
Cash 18.00M 1.72B MRNA
Debt/Equity 0.42 0.09 MRNA
Current Ratio 0.43 2.29 MRNA

Relative Price Performance (Last 90 Days)

FANG 1M: -7.6% · 3M: +1.3% MRNA 1M: +40.0% · 3M: +156.6%

Current Technical Phase

FANG

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 39

RSI (14): 38.9 · Price: $184.38

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64

RSI (14): 63.6 · Price: $196.48

Fundamentals Snapshot

Metric FANG MRNA
Market Cap — —
Forward P/E 9.8 -41.0
Trailing P/E 35.2 —
Revenue (TTM) — —
Revenue Growth 0.5% 0.0%
Gross Margin 0.7% -0.7%
Operating Margin 0.5% -5.6%
EPS 5.25 -7.36
Dividend Yield 0.02% —

Frequently Asked Questions

Based on our detailed analysis, FANG is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.